An update on the use of Pyrilutamide, a new drug for hair loss, which has resulted in no shedding or testicle ache; other users have questioned the science behind this and shared their own experiences with Finasteride, Minoxidil, and microneedling.
The user started using pyrilutamide for hair loss on January 24, applying 1ml daily without other treatments, and after 10 days noticed reduced hair shedding and improved hair quality, with plans to continue for at least 6 months. They experienced chest pain initially, which could be related to starting methylphenidate or pyrilutamide, but the pain has since subsided.
Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.
The conversation discusses the potential of GT20029 to stop hair loss and possibly regrow hair, considering the body's regenerative abilities. No specific treatments were mentioned due to the original post being removed.
The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.
A 24-year-old is struggling with hair loss despite using treatments like dutasteride, oral minoxidil, RU58841, and considering a hair transplant. They are advised to continue medication, possibly increase dosages, and explore additional treatments like tretinoin and tacrolimus.
A 29-year-old male on 1 mg Finasteride for 3 months has experienced a significant increase in testosterone and estradiol levels, with no major side effects except slightly oilier skin and increased emotional sensitivity. The user is concerned about these hormonal changes and seeks advice, as their general practitioner is not knowledgeable about the issue.
The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.
SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.
A user shared their experience with hair loss treatment using finasteride (1mg) and minoxidil (1ml), noting significant shedding phases but hoping for improvement. Shedding is a common synchronized effect of the treatment, which may desynchronize over time, potentially taking over 5 years.
Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.
RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.
A 33-year-old experienced significant hair regrowth on the crown after one year of using oral finasteride (1mg) and minoxidil (2.5mg) daily, with initial concerns about libido that resolved after a week. The user reported minimal shedding and no other side effects, making a hair transplant optional.
A hair transplant of 3361 grafts, 11.5 months after the procedure, that resulted in a very natural looking NW1 hairline; the person who underwent this procedure has not experienced any hair loss and is expecting to have no future hairloss either.
The conversation discusses the safety and effectiveness of a hair loss drug, GT20029, and the possibility of infrequent application, with users hoping for once-daily use and speculating on the drug's duration of effect on the scalp. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
The user experienced hair shedding and follicle shrinkage when using retinoic acid, despite trying different concentrations and frequencies. The hair loss persisted for six months but regrew after stopping the treatment.
The conversation is about the timeline for Kintor's phase 3 trials for GT20029 and the potential release of the product in three years. It also mentions treatments like Minoxidil, finasteride, and RU58841.
A 27-year-old Asian male is treating hair loss with 1mg oral finasteride, topical minoxidil twice daily, and 1.5mm microneedling weekly. The discussion is about his progress with these treatments.
RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.
The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.
Dr. Bloxham's new channel will discuss verteporfin and other future hair loss treatments. Users express interest and hope for the effectiveness of these treatments.
User experienced hair thickening and slight regrowth using RU58841, Fin, DUT, and Minoxidil. They plan to get a hair transplant in Turkey for further improvement.
A group buy for hair loss treatments including Harmine 19a, TM5614, Abiraterone Acetate, and others. A compound, BMS-202, that can potentially reverse gray hair is also mentioned.
KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.
A user shared their positive experience with a 4-in-1 topical solution containing finasteride, minoxidil, ketoconazole, and biotin, along with weekly microneedling using a 1.2mm dermastamp. The user reported no noticeable side effects and mentioned that the biotin likely doesn't contribute to hair growth.
The conversation is about gathering serum DHT data from individuals taking dutasteride to investigate its efficacy, especially in cases with unexpectedly low DHT reduction. The aim is to explore potential genetic factors affecting drug metabolism.
Several users shared their experiences with hair loss treatments, including Minoxidil, Finasteride, and microneedling, reporting varying degrees of hair regrowth. Despite some skepticism, users noted visible improvements over time, with some considering hair transplants as a future option.